NCT06516315

Brief Summary

The main objective of this study is to explore the feasibility of using the angiographic Quantitative Flow Ratio (QFR) as a tool to predict the success rate of endovascular revascularization in patients with superficial artery disease. This is a prospective feasibility study. We aim to include 35 patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery. Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 29, 2024

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 10, 2024

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 23, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 24, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 24, 2025

Completed
Last Updated

July 23, 2024

Status Verified

July 1, 2024

Enrollment Period

12 months

First QC Date

July 10, 2024

Last Update Submit

July 18, 2024

Conditions

Keywords

Lower Limbs Peripheral Arterial Diseaseendovascular procedureangiographic Quantitative Flow Ratio

Outcome Measures

Primary Outcomes (1)

  • Preoperative systolic velocity peak and intraoperative QFR

    Systolic velocity peak measured by preoperative ultrasound, performed the day before or the day of surgery, and QFR measured intraoperatively, immediately before the revascularization procedure.

    Day -1, Day 0

Secondary Outcomes (8)

  • Percentage of stenosis

    Day -1, Day 0

  • Occurrence of a Major Adverse Limb Event (MALE)

    Day 30

  • Re-hospitalization

    Day 30

  • Revascularization

    Day 30

  • Rutherford classification

    Day 30

  • +3 more secondary outcomes

Study Arms (1)

qfr

EXPERIMENTAL

Patients with indication for endovascular revascularization of a short stenosis of the superficial femoral artery (TASC A, Rutherford stage 2 to 6) : * Preoperative ultrasound, performed the day before or the day of surgery * Intraoperative angiography performed immediately prior to revascularization (routine care procedure whose duration is extended by research) * Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.

Procedure: Preoperative ultrasound examination.Procedure: Peroperatoire angiography procedure and QFR analysis

Interventions

Preoperative ultrasound examination performed the day before or the day of surgery.

qfr

Intraoperative angiography will be performed immediately prior to revascularization. Quantitative analysis of angiography images will be performed post-procedure using Medis QFR®2.2 software.

qfr

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with symptomatic Rutherford stage 2 to 6 AOMI with an indication for endovascular revascularization
  • Patient with a simple lesion (TASC A) and short stenosis of the superficial femoral artery
  • Patient affiliated to a health insurance system
  • French-speaking patient
  • Patient with free, informed and express oral consent

You may not qualify if:

  • Renal failure patients with GFR \< 30 ml/min
  • Patient deprived of liberty
  • Patients under court protection
  • Pregnant or breast-feeding patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Paris Saint-Joseph - 185 Rue Raymond Losserand

Paris, Île-de-France Region, 750014, France

RECRUITING

Study Officials

  • Maxime RAUX, Principal investigator

    Fondation Hôpital Saint-Joseph

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michèle LOHORE

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Prospective feasibility study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 10, 2024

First Posted

July 23, 2024

Study Start

April 29, 2024

Primary Completion

April 24, 2025

Study Completion

May 24, 2025

Last Updated

July 23, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Locations